Cargando…
A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass
OBJECTIVE: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. MATERIALS AND METHODS: Prospective single-center...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616869/ https://www.ncbi.nlm.nih.gov/pubmed/37916149 http://dx.doi.org/10.3389/fendo.2023.1181744 |
_version_ | 1785129488717185024 |
---|---|
author | Hernández-Montoliu, Laura Rodríguez-Peña, M-Mar Puig, Rocío Astiarraga, Brenno Guerrero-Pérez, Fernando Virgili, Nuria López-Urdiales, Rafael Osorio, Javier Monseny, Rosa Lazzara, Claudio Sobrino, Lucía Pérez-Maraver, Manuel Pérez-Prieto, María Pellitero, Silvia Fernández-Veledo, Sonia Vendrell, Joan Vilarrasa, Nuria |
author_facet | Hernández-Montoliu, Laura Rodríguez-Peña, M-Mar Puig, Rocío Astiarraga, Brenno Guerrero-Pérez, Fernando Virgili, Nuria López-Urdiales, Rafael Osorio, Javier Monseny, Rosa Lazzara, Claudio Sobrino, Lucía Pérez-Maraver, Manuel Pérez-Prieto, María Pellitero, Silvia Fernández-Veledo, Sonia Vendrell, Joan Vilarrasa, Nuria |
author_sort | Hernández-Montoliu, Laura |
collection | PubMed |
description | OBJECTIVE: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. MATERIALS AND METHODS: Prospective single-center non-randomized controlled study, including patients with class II-III obesity and T2D undergoing mRYGB. At baseline and one year after surgery we performed body composition measurements, biochemical analysis, a meal tolerance test (MTT) and lipid test (LT) with determination of the area under the curve (AUC) for insulin, C-peptide, GLP-1, GLP-2, and fasting determinations of succinate, zonulin, IL-6 and study of gut microbiota. RESULTS: Thirteen patients aged 52.6 ± 6.5 years, BMI 39.3 ± 1.4 kg/m(2), HbA(1c) 7.62 ± 1.5% were evaluated. After mRYGB, zonulin decreased and an increase in AUC after MTT was observed for GLP-1 (pre 9371 ± 5973 vs post 15788 ± 8021 pM, P<0.05), GLP-2 (pre 732 ± 182 vs post 1190 ± 447 ng/ml, P<0.001) and C- peptide, as well as after LT. Species belonging to Streptococaceae, Akkermansiacea, Rickenellaceae, Sutterellaceae, Enterobacteriaceae, Oscillospiraceae, Veillonellaceae, Enterobacterales_uc, and Fusobacteriaceae families increased after intervention and correlated positively with AUC of GLP-1 and GLP-2, and negatively with glucose, HbA(1c), triglycerides and adiposity markers. Clostridium perfringens and Roseburia sp. 40_7 behaved similarly. In contrast, some species belonging to Lachnospiraceae, Erysipelotricaceae, and Rumnicocaceae families decreased and showed opposite correlations. Higher initial C-peptide was the only predictor for T2D remission, which was achieved in 69% of patients. CONCLUSIONS: Patients with obesity and T2D submitted to mRYGB show an enhanced incretin response, a reduced gut permeability and a metabolic improvement, associated with a specific microbiota signature. |
format | Online Article Text |
id | pubmed-10616869 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-106168692023-11-01 A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass Hernández-Montoliu, Laura Rodríguez-Peña, M-Mar Puig, Rocío Astiarraga, Brenno Guerrero-Pérez, Fernando Virgili, Nuria López-Urdiales, Rafael Osorio, Javier Monseny, Rosa Lazzara, Claudio Sobrino, Lucía Pérez-Maraver, Manuel Pérez-Prieto, María Pellitero, Silvia Fernández-Veledo, Sonia Vendrell, Joan Vilarrasa, Nuria Front Endocrinol (Lausanne) Endocrinology OBJECTIVE: To determine changes in incretins, systemic inflammation, intestinal permeability and microbiome modifications 12 months after metabolic RYGB (mRYGB) in patients with type 2 diabetes (T2D) and their relationship with metabolic improvement. MATERIALS AND METHODS: Prospective single-center non-randomized controlled study, including patients with class II-III obesity and T2D undergoing mRYGB. At baseline and one year after surgery we performed body composition measurements, biochemical analysis, a meal tolerance test (MTT) and lipid test (LT) with determination of the area under the curve (AUC) for insulin, C-peptide, GLP-1, GLP-2, and fasting determinations of succinate, zonulin, IL-6 and study of gut microbiota. RESULTS: Thirteen patients aged 52.6 ± 6.5 years, BMI 39.3 ± 1.4 kg/m(2), HbA(1c) 7.62 ± 1.5% were evaluated. After mRYGB, zonulin decreased and an increase in AUC after MTT was observed for GLP-1 (pre 9371 ± 5973 vs post 15788 ± 8021 pM, P<0.05), GLP-2 (pre 732 ± 182 vs post 1190 ± 447 ng/ml, P<0.001) and C- peptide, as well as after LT. Species belonging to Streptococaceae, Akkermansiacea, Rickenellaceae, Sutterellaceae, Enterobacteriaceae, Oscillospiraceae, Veillonellaceae, Enterobacterales_uc, and Fusobacteriaceae families increased after intervention and correlated positively with AUC of GLP-1 and GLP-2, and negatively with glucose, HbA(1c), triglycerides and adiposity markers. Clostridium perfringens and Roseburia sp. 40_7 behaved similarly. In contrast, some species belonging to Lachnospiraceae, Erysipelotricaceae, and Rumnicocaceae families decreased and showed opposite correlations. Higher initial C-peptide was the only predictor for T2D remission, which was achieved in 69% of patients. CONCLUSIONS: Patients with obesity and T2D submitted to mRYGB show an enhanced incretin response, a reduced gut permeability and a metabolic improvement, associated with a specific microbiota signature. Frontiers Media S.A. 2023-10-17 /pmc/articles/PMC10616869/ /pubmed/37916149 http://dx.doi.org/10.3389/fendo.2023.1181744 Text en Copyright © 2023 Hernández-Montoliu, Rodríguez-Peña, Puig, Astiarraga, Guerrero-Pérez, Virgili, López-Urdiales, Osorio, Monseny, Lazzara, Sobrino, Pérez-Maraver, Pérez-Prieto, Pellitero, Fernández-Veledo, Vendrell and Vilarrasa https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Endocrinology Hernández-Montoliu, Laura Rodríguez-Peña, M-Mar Puig, Rocío Astiarraga, Brenno Guerrero-Pérez, Fernando Virgili, Nuria López-Urdiales, Rafael Osorio, Javier Monseny, Rosa Lazzara, Claudio Sobrino, Lucía Pérez-Maraver, Manuel Pérez-Prieto, María Pellitero, Silvia Fernández-Veledo, Sonia Vendrell, Joan Vilarrasa, Nuria A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass |
title | A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass |
title_full | A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass |
title_fullStr | A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass |
title_full_unstemmed | A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass |
title_short | A specific gut microbiota signature is associated with an enhanced GLP-1 and GLP-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic Roux-en-Y gastric bypass |
title_sort | specific gut microbiota signature is associated with an enhanced glp-1 and glp-2 secretion and improved metabolic control in patients with type 2 diabetes after metabolic roux-en-y gastric bypass |
topic | Endocrinology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616869/ https://www.ncbi.nlm.nih.gov/pubmed/37916149 http://dx.doi.org/10.3389/fendo.2023.1181744 |
work_keys_str_mv | AT hernandezmontoliulaura aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT rodriguezpenammar aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT puigrocio aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT astiarragabrenno aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT guerreroperezfernando aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT virgilinuria aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT lopezurdialesrafael aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT osoriojavier aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT monsenyrosa aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT lazzaraclaudio aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT sobrinolucia aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT perezmaravermanuel aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT perezprietomaria aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT pelliterosilvia aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT fernandezveledosonia aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT vendrelljoan aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT vilarrasanuria aspecificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT hernandezmontoliulaura specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT rodriguezpenammar specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT puigrocio specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT astiarragabrenno specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT guerreroperezfernando specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT virgilinuria specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT lopezurdialesrafael specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT osoriojavier specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT monsenyrosa specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT lazzaraclaudio specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT sobrinolucia specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT perezmaravermanuel specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT perezprietomaria specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT pelliterosilvia specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT fernandezveledosonia specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT vendrelljoan specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass AT vilarrasanuria specificgutmicrobiotasignatureisassociatedwithanenhancedglp1andglp2secretionandimprovedmetaboliccontrolinpatientswithtype2diabetesaftermetabolicrouxenygastricbypass |